Gilead, Bristol bow to superiority of CAR-T treatments for blood cancer
VSCompetitive, bespoke CAR-T cell therapies from Gilead Sciences and Bristol Myers Squibb have each demonstrated additional benefits for patients with B cell lymphoma at an earlier stage of treatment than they are currently used for. . But is one better than the other?
The results of the successful clinical trials, dubbed ZUMA-7 and TRANSFORM by Gilead and Bristol, respectively, are presented this weekend at the annual meeting from the American Society of Hematology. Collectively, the data is likely to expand the use of these CAR-T therapies – Yescarta from Gilead and Breyanzi from Bristol – and drive higher sales for both companies.